These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 10982274)

  • 1. Creutzfeldt-Jakob disease and haemophilia: assessment of risk.
    Evatt B
    Haemophilia; 2000 Jul; 6 Suppl 1():94-9. PubMed ID: 10982274
    [No Abstract]   [Full Text] [Related]  

  • 2. Creutzfeldt-Jakob disease.
    Clement P
    Haemophilia; 2000 Jul; 6 Suppl 1():68-78. PubMed ID: 10982271
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical implications of emerging pathogens in haemophilia: the variant Creutzfeldt-Jakob disease experience.
    Dolan G
    Haemophilia; 2006 Mar; 12 Suppl 1():16-20; discussion 26-8. PubMed ID: 16445813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three reported cases of variant Creutzfeldt-Jakob disease transmission following transfusion of labile blood components.
    Hewitt PE; Llewelyn CA; Mackenzie J; Will RG
    Vox Sang; 2006 Nov; 91(4):348. PubMed ID: 17105612
    [No Abstract]   [Full Text] [Related]  

  • 5. Creutzfeldt-Jakob disease and haemophilia: prospect at the new millennium.
    Liras A
    Haemophilia; 2000 Nov; 6(6):716-8. PubMed ID: 11122406
    [No Abstract]   [Full Text] [Related]  

  • 6. Surveillance for Creutzfeldt-Jakob disease among persons with hemophilia.
    Evatt B; Austin H; Barnhart E; Schonberger L; Sharer L; Jones R; DeArmond S
    Transfusion; 1998 Sep; 38(9):817-20. PubMed ID: 9738620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The quandary of Creutzfeldt-Jakob disease.
    Larke B
    CMAJ; 1998 Oct; 159(7):789-92. PubMed ID: 9805025
    [No Abstract]   [Full Text] [Related]  

  • 8. Bleeding and clotting: new therapies and old issues revisited.
    Lee CA; Aledort LM
    Haemophilia; 2009 Mar; 15(2):592-6. PubMed ID: 19335754
    [No Abstract]   [Full Text] [Related]  

  • 9. An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products.
    Turner ML; Ludlam CA
    Br J Haematol; 2009 Jan; 144(1):14-23. PubMed ID: 18950452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of transmission of Creutzfeldt-Jakob disease by transfusion of blood, plasma, and plasma derivatives.
    Vamvakas EC
    J Clin Apher; 1999; 14(3):135-43. PubMed ID: 10540369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New-variant Creutzfeldt-Jakob disease and treatment of haemophilia. Executive Committee UK Haemophilia Directors' Organisation.
    Ludlam CA
    Lancet; 1998 Apr; 351(9111):1289-90. PubMed ID: 9643779
    [No Abstract]   [Full Text] [Related]  

  • 12. Good dental care.
    Brewer AK; Giangrande PL
    Br Dent J; 2005 Feb; 198(4):217. PubMed ID: 15731804
    [No Abstract]   [Full Text] [Related]  

  • 13. New-variant Creutzfeldt-Jakob disease and treatment of haemophilia.
    Baxter T; Black D; Birks D
    Lancet; 1998 Feb; 351(9102):600-1. PubMed ID: 9492811
    [No Abstract]   [Full Text] [Related]  

  • 14. New-variant Creutzfeldt-Jakob disease and treatment of haemophilia. Executive Committee of the UKHCDO. United Kingdom Haemophilia Centre Directors' Organisation.
    Ludlam CA
    Lancet; 1997 Dec; 350(9092):1704. PubMed ID: 9400534
    [No Abstract]   [Full Text] [Related]  

  • 15. [Aspects of the risks associated with vCJK from plasma derivatives from human plasma].
    Burger R; Offergeld R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2009 Jun; 52(6):648-9. PubMed ID: 19557456
    [No Abstract]   [Full Text] [Related]  

  • 16. The pathophysiology of variant Creutzfeldt-Jacob disease: the hypotheses behind concerns for blood components and products.
    Burthem J; Roberts DJ
    Br J Haematol; 2003 Jul; 122(1):3-9. PubMed ID: 12823340
    [No Abstract]   [Full Text] [Related]  

  • 17. Blood supplies hit by vCJD fear.
    Strachan-Bennett S
    Nurs Times; 2004 Jan 6-12; 100(1):6. PubMed ID: 14735624
    [No Abstract]   [Full Text] [Related]  

  • 18. Batch recall of French plasma-derived products due to variant Creutzfeldt-Jakob disease risk: the psychological impact on haemophilic patients, changes in their therapeutic demands and behaviour and ethical considerations.
    Aouba A; Harroche A; Frenzel L; Torchet MF; Rothschild C; François I; Mamzer-Bruneel MF
    Haemophilia; 2015 Jan; 21(1):27-33. PubMed ID: 25545300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Informed consent for creutzfeldt-jakob disease after corneal transplantation.
    Najjar D
    Cornea; 2005 Jan; 24(1):121; author reply 121-2. PubMed ID: 15604881
    [No Abstract]   [Full Text] [Related]  

  • 20. Prions and haemophilia: assessment of risk.
    Evatt BL
    Haemophilia; 1998 Jul; 4(4):628-33. PubMed ID: 9873805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.